Profiling of the Immune Landscape in Murine Glioblastoma Following Blood Brain/tumor Barrier Disruption with MR Image-guided Focused Ultrasound
Overview
Authors
Affiliations
Purpose: Glioblastoma (GB) poses formidable challenges to systemic immunotherapy approaches owing to the paucity of immune infiltration and presence of the blood brain/tumor barriers (BBB/BTB). We hypothesize that BBB/BTB disruption (BBB/BTB-D) with focused ultrasound (FUS) and microbubbles (MB) increases immune infiltration in GB. As a prelude to rational combination of FUS with ITx, we herein investigate the impact of localized BBB/BTB-D on innate and adaptive immune responses in an orthotopic murine GB model.
Methods: Mice with GL261 gliomas received i.v. MB and underwent FUS BBB/BTB-D (1.1 MHz, 0.5 Hz pulse repetition frequency, 10 ms bursts, 0.4-0.6 MPa). Brains, meninges, and peripheral lymphoid organs were excised and examined by flow cytometry 1-2 weeks following FUS.
Results: The number of dendritic cells (DC) was significantly elevated in GL261 tumors and draining cervical LN in response to sonication. CD86 + DC frequency was also upregulated with 0.6 MPa FUS, suggesting increased maturity. While FUS did not significantly alter CD8 + T cell frequency across evaluated organs, these cells upregulated checkpoint molecules at 1 week post-FUS, suggesting increased activation. By 2 weeks post-FUS, we noted emergence of adaptive resistance mechanisms, including upregulation of TIGIT on CD4 + T cells and CD155 on non-immune tumor and stromal cells.
Conclusions: FUS BBB/BTB-D exerts mild, transient inflammatory effects in gliomas-suggesting that its combination with adjunct therapeutic strategies targeting adaptive resistance may improve outcomes. The potential for FUS-mediated BBB/BTB-D to modify immunological signatures is a timely and important consideration for ongoing clinical trials investigating this regimen in GB.
Profile and clinical significance of SPARCL1 and its prognostic significance in breast cancer.
Xu X, Han Y, Song Y, Zhou Z, Chen S, Liu Y Oncol Lett. 2025; 29(4):196.
PMID: 40046638 PMC: 11880884. DOI: 10.3892/ol.2025.14942.
Chen H, Koul D, Zhang Y, Ghobadi S, Zhu Y, Hou Q J Neurooncol. 2024; 170(2):347-361.
PMID: 39180641 DOI: 10.1007/s11060-024-04801-4.
Microbubble-Enhanced Focused Ultrasound for Infiltrating Gliomas.
Seas A, Malla A, Sharifai N, Winkles J, Woodworth G, Anastasiadis P Biomedicines. 2024; 12(6).
PMID: 38927437 PMC: 11200892. DOI: 10.3390/biomedicines12061230.
Fisher D, Sharifi K, Shah I, Gorick C, Breza V, Debski A bioRxiv. 2024; .
PMID: 38352349 PMC: 10862920. DOI: 10.1101/2024.01.31.577810.
Drug resistance in glioblastoma: from chemo- to immunotherapy.
Sharma S, Chepurna O, Sun T Cancer Drug Resist. 2024; 6(4):688-708.
PMID: 38239396 PMC: 10792484. DOI: 10.20517/cdr.2023.82.